Top

Cancer Chemotherapy and Pharmacology

Published in:

Open Access 01-01-2018 | Original Article

The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats

Authors: Nan Li, Bin Chen, Run Lin, Ni Liu, Hai-tao Dai, Ke-yu Tang, Jian-yong Yang, Yong-hui Huang

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2018

Abstract

Purpose

To investigate the optimal starting time point of sorafenib therapy in suppressing the tumor-promoting effects of VEGF up-regulation, which is frequently found after local therapy in clinical practice.

Methods

VEGF was intravenously injected to imitate the evaluated expression after local tumor therapy, such as TACE. A total of 40 SD rats bearing hepatic tumors were randomly divided into four groups and sorafenib was administered at different timepoints: (A) control group: VEGF injection only; (B) initiating sorafenib 72 h prior to VEGF injection; (C) initiating sorafenib simultaneously with VEGF injection; (D) initiating sorafenib 72 h post-VEGF injection. The rate of tumor growth, median survival time, expression of VEGF, and microvessel density (MVD), as determined by immunohistochemical (IHC) examination, were compared.

Results

The results revealed that the tumor size and median survival time were significantly different between the three sorafenib groups compared to the control group (p < 0.05). Median survival times were 19.6 ± 1.78, 31.2 ± 6.99, 27.4 ± 4.9, and 26.5 ± 4.6 days in group A, B, C, and D, respectively. Furthermore, there was a difference in statistical significance between the two sorafenib groups B and D (p = 0.04). Tumors were collected for HE staining and IHC examination. The expression levels of VEGF in B, C, and D were 42.8 ± 7.96, 71.9 ± 15.73, and 73.6 ± 13.73, and all of them were significantly lower than that in the control group (88.3 ± 13.61). Furthermore, the level of MVD was 109.2 ± 8.98 in the control group, which was significantly higher than in the three sorafenib groups (45.7 ± 16.92, 77.1 ± 16.29, and 93.6 ± 12.87, all p < 0.05).

Conclusions

According to our results, the most suitable regimen for the administration of sorafenib is before the increased expression of VEGF, which showed a potential advantage for controlling the tumor growth and prolonging the survival time of test animal via inhibiting VEGF-receptor expression through the bifunction of VEGF, and the reduction of tumor angiogenesis.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262 CrossRefPubMed

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. https://doi.org/10.1002/ijc.29210 CrossRefPubMed

Kodera Y, Fujitani K, Fukushima N, Ito S, Muro K, Ohashi N, Yoshikawa T, Kobayashi D, Tanaka C, Fujiwara M (2014) Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc 17(2):206–212. https://doi.org/10.1007/s10120-013-0299-x

Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022. https://doi.org/10.1002/hep.24199 CrossRefPubMedPubMedCentral

Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148(2):397–401. https://doi.org/10.1148/radiology.148.2.6306721 CrossRefPubMed

Zhao J, Zhang H, Wei L, Xie S, Suo Z (2017) Comparing the long-term efficacy of standard and combined minimally invasive procedures for unresectable HCC: a mixed treatment comparison. Oncotarget 8(9):15101–15113. https://doi.org/10.18632/oncotarget.13145 PubMed

Minagawa M, Makuuchi M (2006) Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 12(47):7561–7567CrossRefPubMedPubMedCentral

Collaborators: Llovet JM DM, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JFGT, Raymond E, Roskams T, De Baere T, Ducreux M, Mazzaferro VMB (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943. https://doi.org/10.1016/j.jhep.2011.12.001 CrossRef

Li X, Feng GS, Zheng CS, Zhuo CK, Liu X (2004) Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 10(19):2878–2882CrossRefPubMedPubMedCentral

10.

Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW (2008) Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol (Stockholm Sweden 1987) 49(5):523–529. https://doi.org/10.1080/02841850801958890 CrossRef

11.

Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57(4):821–829. https://doi.org/10.1016/j.jhep.2012.06.014 CrossRefPubMed

12.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390. https://doi.org/10.1056/NEJMoa0708857 CrossRefPubMed

13.

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34. https://doi.org/10.1016/s1470-2045(08)70285-7 CrossRefPubMed

14.

Rimassa L, Pressiani T, Boni C, Carnaghi C, Rota Caremoli E, Fagiuoli S, Foa P, Salvagni S, Cortesi E, Chiara Tronconi M, Personeni N, Bozzarelli S, Chiara Banzi M, Fanello S, Romano Lutman F, Giordano L, Santoro A (2013) A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma. Oncologist 18(4):379–380. https://doi.org/10.1634/theoncologist.2012-0221 CrossRefPubMedPubMedCentral

15.

Lu XJ, Dong J, Ji LJ, Luo JH, Cao HM, Xiao LX, Zhou J, Ling CQ (2016) Safety and efficacy of TACE and gamma knife on hepatocellular carcinoma with portal vein invasion. Gut 65(4):715–716. https://doi.org/10.1136/gutjnl-2015-310292 CrossRefPubMed

16.

Nishikawa H, Takeda H, Tsuchiya K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y, Osaki Y, Izumi N (2014) Sorafenib therapy for BCLC stage B/C hepatocellular carcinoma; clinical outcome and safety in aged patients: a multicenter study in Japan. J Cancer 5(7):499–509CrossRefPubMedPubMedCentral

17.

Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF (2011) Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 29(30):3960–3967. https://doi.org/10.1200/jco.2011.37.1021 CrossRefPubMedPubMedCentral

18.

Huang Y, Chen B, Liu N, Li N, Dao H, Chen W, Yang J (2017) Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis. Int J Clin Pharmacol Ther 55(6):498–508. https://doi.org/10.5414/cp202787 CrossRefPubMed

19.

Strebel BM, Dufour JF (2008) Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 8(11):1743–1749. https://doi.org/10.1586/14737140.8.11.1743 CrossRefPubMed

20.

Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K (2011) Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer (Oxford England 1990) 47(14):2117–2127. https://doi.org/10.1016/j.ejca.2011.05.007 CrossRef

21.

Abou-Alfa GK (2011) TACE and sorafenib: a good marriage? J Clin Oncol 29(30):3949–3952. https://doi.org/10.1200/jco.2011.37.9651 CrossRefPubMed

22.

Vicentino C, Constantin J, Aparecido Stecanella L, Bracht A, Yamamoto NS (2002) Glucose and glycogen catabolism in perfused livers of Walker-256 tumor-bearing rats and the response to hormones. Pathophysiology 8(3):175–182CrossRefPubMed

23.

Pigatto MC, Roman RM, Carrara L, Buffon A, Magni P, Dalla Costa T (2017) Pharmacokinetic/pharmacodynamic modeling of etoposide tumor growth inhibitory effect in Walker-256 tumor-bearing rat model using free intratumoral drug concentrations. Eur J Pharm Sci 97:70–78. https://doi.org/10.1016/j.ejps.2016.10.038 CrossRefPubMed

24.

Vicentino C, Constantin J, Bracht A, Yamamoto NS (2002) Long-chain fatty acid uptake and oxidation in the perfused liver of Walker-256 tumour-bearing rats. Liver 22(4):341–349CrossRefPubMed

25.

Zhang Y, Li M, Wei L, Zhu L, Hu S, Wu S, Ma S, Gao Y (2013) Differential protein expression in perfusates from metastasized rat livers. Proteom Sci 11(1):37. https://doi.org/10.1186/1477-5956-11-37 CrossRef

26.

Guo WJ, Li J, Chen Z, Zhuang JY, Gu WH, Zhang L, Pang J, Lu CH, Zhang WZ, Cheng YF (2004) Transient increased expression of VEGF and MMP-1 in a rat liver tumor model after hepatic arterial occlusion. Hepatogastroenterology 51(56):381–386PubMed

27.

Liu N, Yang J, Huang Y, Chen B, Chen W, Li J (2015) Vascular endothelial growth factor accelerates establishment of a model of hepatic metastasis in Walker-256 tumor-bearing rats. Am J Med Sci 349(3):234–239. https://doi.org/10.1097/maj.0000000000000359 CrossRefPubMed

28.

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66(24):11851–11858. https://doi.org/10.1158/0008-5472.can-06-1377 CrossRefPubMed

29.

Cheng D, Xu H, Hua R, Xu K, Lv W, Lu X, Du H, Zhang Q (2015) Comparative study of MRI manifestations of acute and chronic Budd-Chiari syndrome. Abdom Imaging 40(1):76–84. https://doi.org/10.1007/s00261-014-0193-y CrossRefPubMed

30.

Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med 324(1):1–8. https://doi.org/10.1056/nejm199101033240101 CrossRefPubMed

31.

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. Ca Cancer J Clin 66(1):7CrossRefPubMed

32.

Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxi A, Cottone M (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224(1):47–54. https://doi.org/10.1148/radiol.2241011262 CrossRefPubMed

33.

Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429–442. https://doi.org/10.1053/jhep.2003.50047 CrossRefPubMed

34.

Kirsch M, Schackert G, Black PM (2004) Metastasis and angiogenesis. Cancer Treat Res 117:285–304CrossRefPubMed

35.

Gupta MK, Qin RY (2003) Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 9(6):1144–1155CrossRefPubMedPubMedCentral

36.

Patel N, Harris AL, Gleeson FV, Vallis KA (2012) Clinical imaging of tumor angiogenesis. Future Oncol (London England) 8(11):1443–1459. https://doi.org/10.2217/fon.12.136 CrossRef

37.

Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA (2009) Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 115(21):4895–4906. https://doi.org/10.1002/cncr.24537 CrossRefPubMed

38.

Hsieh MY, Lin ZY, Chuang WL (2011) Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization. Kaohsiung J Med Sci 27(8):314–322. https://doi.org/10.1016/j.kjms.2011.03.008 CrossRefPubMed

39.

Suzuki H, Mori M, Kawaguchi C, Adachi M, Miura S, Ishii H (1999) Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma. Int J Oncol 14(6):1087–1090PubMed

40.

Li Y, Zhai Z, Liu D, Zhong X, Meng X, Yang Q, Liu J, Li H (2015) CD105 promotes hepatocarcinoma cell invasion and metastasis through VEGF. Tumour Biol 36(2):737–745. https://doi.org/10.1007/s13277-014-2686-2 CrossRefPubMed

41.

Pereira T, Dodal S, Tamgadge A, Bhalerao S, Tamgadge S (2016) Quantitative evaluation of microvessel density using CD34 in clinical variants of ameloblastoma: an immunohistochemical study. J Oral Maxillofac Pathol 20(1):51–58. https://doi.org/10.4103/0973-029x.180929 CrossRefPubMedPubMedCentral

42.

Nowak AK, Chow PK, Findlay M (2004) Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer (Oxford England 1990) 40(10):1474–1484. https://doi.org/10.1016/j.ejca.2004.02.027 CrossRef

43.

Pawarode A, Tangkijvanich P, Voravud N (2000) Outcomes of primary hepatocellular carcinoma treatment: an 8-year experience with 368 patients in Thailand. J Gastroenterol Hepatol 15(8):860–864CrossRefPubMed

44.

Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA (2005) The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24(46):6861–6869. https://doi.org/10.1038/sj.onc.1208841 CrossRefPubMed

45.

Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z, Kickuth R, Borner M, Candinas D, Saar B (2010) Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist 15(11):1198–1204. https://doi.org/10.1634/theoncologist.2010-0180 CrossRefPubMedPubMedCentral

Title: The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats
Authors: Nan Li
Bin Chen
Run Lin
Ni Liu
Hai-tao Dai
Ke-yu Tang
Jian-yong Yang
Yong-hui Huang
Publication date: 01-01-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3493-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease

Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects

Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial)

A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer

Correction to: Innovative intraoral cooling device better tolerated and equally effective as ice cooling

Keynote webinar | Spotlight on antibody–drug conjugates in cancer